cervical cancer
Conditions
Interventions
Single Arm:Sintilimab should be administered every 3 weeks (Q3W).
Sponsors
Department of oncology, The Third Affiliated Hospital of Chongqing Medical University(Gener Hospita)
Eligibility
Sex/Gender
Female
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Histologically or cytologically confirmed locally advanced cervical cancer, including squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma; 2. FIGO 2018 are: IB3, IIA2, IIB~IVA stage of locally advanced cancer 3. ECOG score: 0-2 4. Female, ages 18-75 5. There were no serious damage to the function of major organs in the whole body and no other primary malignant tumors 6. Blood routine, biochemistry, electrocardiogram and other examinations were within the normal range 7. No previous use of immune checkpoint inhibitors 8. Subjects should have tumor tissue samples before concurrent chemoradiotherapy to provide PD-L1 detection 9. At least one objectively evaluable lesion (RECIST 1.1) 10. The subjects voluntarily joined the study, signed informed consent, had good compliance, and cooperated with follow-up
Exclusion criteria
Exclusion criteria: 1. Subjects requiring systemic treatment with corticosteroids (> 10mg/ day equivalent dose of prednisone) or other immunosuppressant drugs within 14 days prior to study drug administration 2. Patients with incomplete medical records 3. Inability or unwillingness to actively cooperate with trial investigators 4. Combined with other diseases that seriously affect the course of treatment 5. Participants who had participated in other antitumor drug clinical trials within 4 weeks prior to enrollment 6. Patients who are allergic to sintilimab or chemotherapy drugs 7. The investigator determines other circumstances that may affect the conduct of the clinical study and the determination of the study results
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ORR; | — |
Secondary
| Measure | Time frame |
|---|---|
| PFS;OS; | — |
Countries
China
Contacts
Public ContactMeiling LAN
Department of oncology, The Third Affiliated Hospital of Chongqing Medical University(Gener Hospita)
Outcome results
None listed